美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

冠軍工業

0.0200

0.0000

成交量：- -

成交額：- -

市值：1,117.14

市盈率：0.00

高：0.0200

開：0.0200

低：0.0200

收：0.0200

52周最高：0.0200

52周最低：0.0001

股本：5.59萬

流通股本：- -

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-23.0334

每股收益(LYR):-23.0334

淨資產收益率：-49.45%

總資產收益率：-1.87%

市淨率：0.00

市盈率(LYR):0.00

資料載入中...

總覽公司新聞資訊公告

持續創新穩拓全球

复星医药官微

復宏漢霖(02696)：帕妥珠單抗生物類似藥HLX11(重組抗HER2結構域II人源化單克隆抗體注射液)獲歐洲藥品管理局(EMA)人用醫藥產品委員會(CHMP)積極審評意見

更高效劑量的Wegovy注射液獲歐盟委員會批准

21世纪经济报道

甘李藥業(603087.SH)：甘精胰島素注射液(Ondibta®)上市許可申請(MAA)獲得歐盟CHMP積極意見

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/CHMP/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CHMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","market":"US","secType":"STK","nameCN":"冠軍工業","latestPrice":0.02,"timestamp":1772571600000,"preClose":0.02,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":0,"shares":55857,"eps":-23.033406,"marketStatus":"盤後交易","change":0,"latestTime":"03-03 16:00:00 EST 延時","open":0.02,"high":0.02,"low":0.02,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-23.033406,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1772586000000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.02,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHMP\",,,,,undefined,":{"symbol":"CHMP","floatShares":0,"roa":"-1.87%","roe":"-49.45%","lyrEps":-23.033406,"shares":55857,"dividePrice":0,"high":0.02,"amplitude":0,"preClose":0.02,"low":0.02,"week52Low":0.0001,"pbRate":"0.00","psRate":"0.00","week52High":0.02,"institutionHeld":0,"latestPrice":0.02,"eps":-23.033406,"divideRate":0,"volume":0,"delay":15,"ttmEps":-23.033406,"open":0.02,"prevYearClose":0.02,"prevWeekClose":0.02,"prevMonthClose":0.02,"prevQuarterClose":0.02,"fiveDayClose":0.02,"twentyDayClose":0.02,"sixtyDayClose":0.0001},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHMP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHMP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CHMP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHMP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2616533009","title":"持續創新 穩拓全球","url":"https://stock-news.laohu8.com/highlight/detail?id=2616533009","media":"复星医药官微","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616533009?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 21:49","pubTimestamp":1772459340,"startTime":"0","endTime":"0","summary":"创新抗PD-1单抗汉斯状 迈向更广阔国际市场，复星医药子公司复宏汉霖再拓全球布局03汉利康上市七周年 | 以实证行致远，引领一个更可及的治疗时代七年，足以让一粒创新的种子长成惠及数十万患者的生命之树；七年，也见证了中国首个生物类似药从“破冰者”到“领航者”的征程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-03-02/doc-inhprfsh8091981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02196","BK1515","BK1593","BK4087","EMA","BK1191","CHMP","BK4081"],"gpt_icon":0},{"id":"2614085473","title":"復宏漢霖(02696)：帕妥珠單抗生物類似藥HLX11(重組抗HER2結構域II人源化單克隆抗體注射液)獲歐洲藥品管理局(EMA)人用醫藥產品委員會(CHMP)積極審評意見","url":"https://stock-news.laohu8.com/highlight/detail?id=2614085473","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614085473?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 22:27","pubTimestamp":1772202451,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，HLX11获EMA人用医药产品委员会积极审评意见，推荐批准HLX11的上市许可申请。倘若获得EC批准，HLX11的集中上市许可将在所有欧盟成员国及欧洲经济区国家冰岛、列支敦士登和挪威生效。HLX11是本公司自主研发的帕妥珠单抗生物类似药。2024年12月，HLX11的上市注册申请获国家药品监督管理局受理。2025年3月，HLX11的上市许可申请获欧洲药品管理局受理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","HK0000320264.USD","BK1161","02696","HK0000320223.HKD","CHMP","159938","BK4081","BK1574","BK4087","BK1515","EMA","HK0000165453.HKD","HK0000306685.HKD","09939"],"gpt_icon":0},{"id":"2614880689","title":"更高效劑量的Wegovy注射液獲歐盟委員會批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2614880689","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614880689?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 16:24","pubTimestamp":1772180681,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者韩利明2月27日消息显示，欧盟委员会已批准Wegovy?（司美格鲁肽注射液）新的7.2mg每周一次维持剂量，用于成人肥胖症患者。这一批准为医生提供了新的治疗选择，以帮助使用2.4mg剂量后仍需更多减重的成人患者。此项批准决定基于欧洲药品管理局人用药品委员会（CHMP）于2025年12月12日发布的积极审评意见。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602273656670689.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656670689.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CHMP","BK4087"],"gpt_icon":0},{"id":"2583550301","title":"甘李藥業(603087.SH)：甘精胰島素注射液(Ondibta®)上市許可申請(MAA)獲得歐盟CHMP積極意見","url":"https://stock-news.laohu8.com/highlight/detail?id=2583550301","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583550301?lang=zh_tw&edition=fundamental","pubTime":"2025-11-13 17:17","pubTimestamp":1763025442,"startTime":"0","endTime":"0","summary":"CHMP 建议欧盟委员会批准甘精胰岛素注射液作为 Lantus SoloStar 的生物类似药上市，用于治疗成人、青少年和2岁及以上儿童的糖尿病。CHMP的建议将进入EC审查阶段，以获得Ondibta在欧盟、冰岛、列支敦士登和挪威的上市许可，最终决定预计将于明年初做出。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4087","BK4215","FESXmain","BK0239","MAA","603087","BK4585","FSXEmain","CHMP","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}]}}